Here's Why Shareholders Should Examine Proteome Sciences plc's (LON:PRM) CEO Compensation Package More Closely
May 10
U.K. (FTSE) Life Sciences Industry Analysis
UpdatedJul 19, 2024
DataAggregated Company Financials
Companies9
- 7D6.5%
- 3M17.8%
- 1Y-43.1%
- YTD-31.0%
In the last week, the Life Sciences industry is up 6.5%, with Oxford Nanopore Technologies up 5.3%. Meanwhile, Proteome Sciences actually underperformed within the industry, shrinking 7.6% in the last week. However, the industry is down 43% over the past year. Looking forward, earnings are forecast to grow by 17% annually.
Industry Valuation and Performance
Has the U.K. Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 20 Jul 2024 | UK£1.7b | UK£295.2m | -UK£189,645,167.49 | 12.8x | -9.1x | 5.9x |
| Mon, 17 Jun 2024 | UK£1.6b | UK£295.8m | -UK£189,931,418.67 | 11.6x | -8.2x | 5.3x |
| Wed, 15 May 2024 | UK£1.6b | UK£294.9m | -UK£187,719,596.75 | 7219.4x | -8.8x | 5.6x |
| Fri, 12 Apr 2024 | UK£1.6b | UK£317.5m | -UK£178,304,928.83 | 12.5x | -9.1x | 5.1x |
| Sun, 10 Mar 2024 | UK£1.9b | UK£292.8m | -UK£212,325,303.08 | 7210.6x | -9x | 6.5x |
| Tue, 06 Feb 2024 | UK£2.1b | UK£286.1m | -UK£189,521,420.51 | 6862.3x | -11.2x | 7.4x |
| Thu, 04 Jan 2024 | UK£3.1b | UK£450.1m | -UK£174,171,467.00 | 62x | -17.8x | 6.9x |
| Sat, 02 Dec 2023 | UK£3.1b | UK£455.2m | -UK£168,866,409.00 | 50.7x | -18.2x | 6.7x |
| Mon, 30 Oct 2023 | UK£3.0b | UK£458.8m | -UK£165,732,145.00 | 46.7x | -18x | 6.5x |
| Wed, 27 Sep 2023 | UK£3.0b | UK£448.1m | -UK£167,589,158.00 | 67.5x | -17.9x | 6.7x |
| Fri, 25 Aug 2023 | UK£3.1b | UK£476.4m | -UK£126,694,329.00 | 70.6x | -24.5x | 6.5x |
| Sun, 23 Jul 2023 | UK£3.5b | UK£476.2m | -UK£124,493,188.00 | 69.6x | -27.8x | 7.3x |
| Tue, 20 Jun 2023 | UK£3.0b | UK£476.4m | -UK£124,608,651.00 | 64.4x | -23.7x | 6.2x |
| Thu, 18 May 2023 | UK£3.1b | UK£477.8m | -UK£122,766,226.00 | 36.3x | -25.6x | 6.6x |
| Sat, 15 Apr 2023 | UK£3.2b | UK£458.8m | -UK£118,914,825.00 | 35.5x | -27.2x | 7.1x |
| Mon, 13 Mar 2023 | UK£2.9b | UK£443.7m | -UK£183,261,487.00 | 42.3x | -16x | 6.6x |
| Wed, 08 Feb 2023 | UK£3.5b | UK£443.7m | -UK£183,126,324.00 | 47.1x | -19x | 7.9x |
| Fri, 06 Jan 2023 | UK£3.5b | UK£444.1m | -UK£183,277,828.00 | 49.6x | -19.3x | 8x |
| Sun, 04 Dec 2022 | UK£3.7b | UK£446.3m | -UK£178,824,932.00 | 51.8x | -20.9x | 8.4x |
| Tue, 01 Nov 2022 | UK£3.6b | UK£448.3m | -UK£176,138,751.00 | 45.9x | -20.7x | 8.1x |
| Thu, 29 Sep 2022 | UK£3.3b | UK£450.7m | -UK£177,340,781.00 | 42.3x | -18.9x | 7.4x |
| Sat, 27 Aug 2022 | UK£3.7b | UK£369.7m | -UK£189,865,707.00 | 45.6x | -19.3x | 9.9x |
| Mon, 25 Jul 2022 | UK£3.7b | UK£366.8m | -UK£188,140,292.00 | 39x | -19.9x | 10.2x |
| Wed, 22 Jun 2022 | UK£3.8b | UK£363.8m | -UK£189,467,535.00 | 37.6x | -20.2x | 10.5x |
| Fri, 20 May 2022 | UK£3.7b | UK£361.3m | -UK£191,569,540.00 | 41.4x | -19.3x | 10.2x |
| Sun, 17 Apr 2022 | UK£6.2b | UK£929.9m | -UK£312,315,184.00 | 48.5x | -19.9x | 6.7x |
| Tue, 15 Mar 2022 | UK£6.6b | UK£892.0m | -UK£203,309,156.00 | 43.6x | -32.4x | 7.4x |
| Thu, 10 Feb 2022 | UK£8.0b | UK£848.8m | -UK£185,919,961.00 | 30.8x | -42.9x | 9.4x |
| Sat, 08 Jan 2022 | UK£8.9b | UK£849.0m | -UK£184,395,837.00 | 31.1x | -48x | 10.4x |
| Mon, 06 Dec 2021 | UK£9.2b | UK£844.3m | -UK£192,212,129.00 | 26.3x | -47.9x | 10.9x |
| Wed, 03 Nov 2021 | UK£8.3b | UK£841.0m | -UK£202,675,668.00 | 26.1x | -41.1x | 9.9x |
| Fri, 01 Oct 2021 | UK£3.0b | UK£706.2m | -UK£129,725,693.00 | 29.2x | -23.2x | 4.3x |
| Sun, 29 Aug 2021 | UK£3.1b | UK£670.4m | -UK£160,499,800.35 | 69.6x | -19.4x | 4.7x |
Price to Earnings Ratio
-18.2x
Current Industry PE
- Investors are pessimistic on the British Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 8.6x is higher than the industry's current PS ratio of 5.9x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have deteriorated over the last three years.
- Revenues have also declined 24% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the U.K. Healthcare industry?
| GB Market | -0.11% | |
| Healthcare | 0.69% | |
| Life Sciences | 6.46% | |
| Clinical Research and Equipment | 6.46% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ONT Oxford Nanopore Technologies | UK£1.11 | 5.3% +UK£48.9m | -59.4% | PS5.7x | |
| MXCT MaxCyte | UK£3.80 | 9.2% +UK£33.5m | 0% | PS11.7x | |
| HVO hVIVO | UK£0.30 | 12.6% +UK£23.1m | 94.9% | PE12.8x | |
| ERGO Ergomed | UK£13.46 | 0.1% +UK£14.7m | 3.5% | PE46.7x | |
| C4XD C4X Discovery Holdings | UK£0.12 | 45.9% +UK£9.5m | -16.4% | PE2.9x |